GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (BSP:B1ME34) » Definitions » Cash Flow for Dividends

BeOne Medicines (BSP:B1ME34) Cash Flow for Dividends : R$0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BeOne Medicines Cash Flow for Dividends?

BeOne Medicines's cash flow for dividends for the three months ended in Dec. 2024 was R$0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2024 was R$0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

BeOne Medicines Cash Flow for Dividends Historical Data

The historical data trend for BeOne Medicines's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines Cash Flow for Dividends Chart

BeOne Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BeOne Medicines Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BeOne Medicines Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

BeOne Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (BSP:B1ME34) » Definitions » Cash Flow for Dividends
Comparable Companies
BNTX ALNY SMMT UTHR INSM RPRX INCY MRNA BMRN EXEL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB XKRX:068270 XKRX:196170 OCSE:GMAB HKSE:02269
Traded in Other Exchanges
BEIGF:USA ONC:USA 06160:Hong Kong 49B:Germany 688235:China
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Website
https://www.beigene.com
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

BeOne Medicines Headlines

No Headlines